

Anne Chauchereau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2130059/publications.pdf>

Version: 2024-02-01

47
papers

1,746
citations

257450

24
h-index

345221

36
g-index

50
all docs

50
docs citations

50
times ranked

2727
citing authors

#	ARTICLE	IF	CITATIONS
1	A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. <i>British Journal of Cancer</i> , 2011, 105, 847-853.	6.4	369
2	A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced Disease. <i>Cancer Research</i> , 2013, 73, 86-96.	0.9	142
3	Sumoylation of the Progesterone Receptor and of the Steroid Receptor Coactivator SRC-1. <i>Journal of Biological Chemistry</i> , 2003, 278, 12335-12343.	3.4	125
4	JAB1 Interacts with Both the Progesterone Receptor and SRC-1. <i>Journal of Biological Chemistry</i> , 2000, 275, 8540-8548.	3.4	97
5	The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. <i>European Journal of Cancer</i> , 2010, 46, 1770-1772.	2.8	83
6	HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF. <i>Oncogene</i> , 2004, 23, 8777-8784.	5.9	69
7	E2F3 Is a Mediator of DNA Damage-Induced Apoptosis. <i>Molecular and Cellular Biology</i> , 2010, 30, 524-536.	2.3	67
8	The postchemotherapy PSA surge syndrome. <i>Annals of Oncology</i> , 2008, 19, 1308-1311.	1.2	60
9	Ligand-Controlled Interaction of Histone Acetyltransferase Binding to ORC-1 (HBO1) with the N-Terminal Transactivating Domain of Progesterone Receptor Induces Steroid Receptor Coactivator 1-Dependent Coactivation of Transcription. <i>Molecular Endocrinology</i> , 2006, 20, 2122-2140.	3.7	57
10	Control of Biosynthesis and Post-Transcriptional Modification of the Progesterone Receptor. <i>Biology of Reproduction</i> , 1992, 46, 174-177.	2.7	50
11	Subcellular Localization and Mechanisms of Nucleocytoplasmic Trafficking of Steroid Receptor Coactivator-1. <i>Journal of Biological Chemistry</i> , 2003, 278, 32195-32203.	3.4	45
12	Bioresponsive hyperbranched polymers for siRNA and miRNA delivery. <i>Journal of Drug Targeting</i> , 2010, 18, 812-820.	4.4	43
13	Differential Recruitment of p160 Coactivators by Glucocorticoid Receptor between Schwann Cells and Astrocytes. <i>Molecular Endocrinology</i> , 2006, 20, 254-267.	3.7	42
14	Selective Recruitment of p160 Coactivators on Glucocorticoid-Regulated Promoters in Schwann Cells. <i>Molecular Endocrinology</i> , 2004, 18, 2866-2879.	3.7	41
15	Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2010, 21, 1864-1869.	1.2	40
16	Co-operation of progestational steroids with epidermal growth factor in activation of gene expression in mammary tumor cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1991, 40, 239-245.	2.5	38
17	Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer. <i>Oncotarget</i> , 2017, 8, 44654-44668.	1.8	35
18	Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer. <i>Oncotarget</i> , 2014, 5, 667-678.	1.8	34

#	ARTICLE	IF	CITATIONS
19	Personalizing treatment in patients with castrate-resistant prostate cancer: A study of predictive factors for secondary endocrine therapies activity.. Journal of Clinical Oncology, 2012, 30, 213-213.	1.6	32
20	Involvement of β -catenin and unusual behavior of CBP and p300 in glucocorticosteroid signaling in Schwann cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14260-14265.	7.1	29
21	The IGR-CaP1 Xenograft Model Recapitulates Mixed Osteolytic/Blastic Bone Lesions Observed in Metastatic Prostate Cancer. Neoplasia, 2012, 14, 376-IN1.	5.3	29
22	Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis. EMBO Molecular Medicine, 2016, 8, 761-778.	6.9	27
23	Phosphorylation Sites in Ligand-Induced and Ligand-Independent Activation of the Progesterone Receptor. Biochemistry, 1994, 33, 13295-13303.	2.5	26
24	Ligand-Dependent Degradation of SRC-1 Is Pivotal for Progesterone Receptor Transcriptional Activity. Molecular Endocrinology, 2011, 25, 394-408.	3.7	26
25	Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer. Experimental Cell Research, 2011, 317, 262-275.	2.6	25
26	Functional Assessment of Genetic Variants with Outcomes Adapted to Clinical Decision-Making. PLoS Genetics, 2016, 12, e1006096.	3.5	24
27	Compound Functional Prediction Using Multiple Unrelated Morphological Profiling Assays. SLAS Technology, 2018, 23, 243-251.	1.9	16
28	Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 710-723.	7.0	12
29	Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome. , 2020, 8, e001535.		11
30	Automation of a chloramphenicol acetyltransferase assay. Analytical Biochemistry, 1990, 188, 310-316.	2.4	10
31	A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector. Oncotarget, 2017, 8, 12272-12289.	1.8	9
32	Effects of FSH and 17β -estradiol on the transactivation of estrogen-regulated promoters and cell proliferation in L cells. Journal of Steroid Biochemistry and Molecular Biology, 2005, 94, 289-302.	2.5	6
33	Experimental models for the development of new medical treatments in prostate cancer. European Journal of Cancer, 2011, 47, S200-S214.	2.8	6
34	The quest for the "bony Grail" of detecting circulating tumour cells in patients with prostate cancer. Annals of Oncology, 2009, 20, 197-199.	1.2	5
35	Progress in the study of receptors involved in steroidogenesis and steroid hormone action. Journal of Steroid Biochemistry and Molecular Biology, 1991, 40, 21-23.	2.5	4
36	The benefit of combining docetaxel to androgen deprivation therapy in localized and metastatic castration-sensitive prostate cancer as predicted by ERG status: An analysis of two GETUG phase III trials.. Journal of Clinical Oncology, 2017, 35, 5012-5012.	1.6	4

#	ARTICLE	IF	CITATIONS
37	A study of ERG, PTEN, and ki-67 in a phase III trial assessing docetaxel and estramustine in high-risk localized prostate cancer (GETUG 12).. Journal of Clinical Oncology, 2014, 32, 5063-5063.	1.6	3
38	Abstract 1597: A novel preclinical model of prostate cancer bone metastasis derived from a human primary tumor. , 2011, , .		1
39	Abstract 2995: Loss of SHISA3 is an early event of the epithelial-to-mesenchymal transition associated with chemoresistance in prostate cancer. , 2015, , .		1
40	Abstract 4339: Prostate adenocarcinoma and intensive bone remodeling in a new prostate cancer IGR-CaP1 preclinical model derived from a human primary tumor. , 2010, , .		1
41	Abstract 823: Integration of microRNA and gene expression signatures from several models of Docetaxel-resistant prostate cancer cell lines. , 2012, , .		0
42	Abstract 956: Role of the cell cycle regulator LZTS1 in docetaxel resistance of prostate cancer cells and overcoming the docetaxel resistance by cell cycle pharmacological inhibitors.. , 2013, , .		0
43	Abstract 4466: New biomarkers to optimize preclinical development of the PDI inhibitor XCE853. , 2015, , .		0
44	Abstract 3948: Identification of a new therapeutic target in prostate cancer from siRNA screening in Docetaxel-resistant cells. , 2015, , .		0
45	Abstract 3760: XCE853 is a promising protein disulfide isomerase (PDI) inhibitor exhibiting a strong inhibitory activity in preclinical tumor models. , 2016, , .		0
46	Abstract 892: ROCK dependent signalling pathways contribution to collective invasion of colorectal carcinoma. , 2017, , .		0
47	Abstract 1138: The protein disulfide isomerase inhibitor XCE853 inhibits in vitro, ex-vivo and in vivo growth of human tumors. , 2017, , .		0